Paper41892463
Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.
Yucel E and 7 others. Antibiotics (Basel), 2026. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis. Papers, record 41892463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41892463
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N/A | Merck Sharp & Dohme LLC | PubMed |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36,647,284 | Infections and immunity: associations with obesity and related metabolic disorders. | J Pathol Transl Med | 2023 | https://conductscience.org/library/papers/36647284 | PubMed |
| 2 | 33,831,296 | Obesity and chronic kidney disease: prevalence, mechanism, and management. | Clin Exp Pediatr | 2021 | https://conductscience.org/library/papers/33831296 | PubMed |
| 3 | 29,934,432 | Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. | Clin J Am Soc Nephrol | 2018 | https://conductscience.org/library/papers/29934432 | PubMed |
| 4 | 38,526,051 | Updated antimicrobial dosing recommendations for obese patients. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38526051 | PubMed |
| 5 | 38,570,631 | Chronic kidney disease and the global public health agenda: an international consensus. | Nat Rev Nephrol | 2024 | https://conductscience.org/library/papers/38570631 | PubMed |
| 6 | 36,551,426 | Antibiotic Therapy in the Critically Ill with Acute Renal Failure and Renal Replacement Therapy: A Narrative Review. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/36551426 | PubMed |
| 7 | 36,498,473 | Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. | J Clin Med | 2022 | https://conductscience.org/library/papers/36498473 | PubMed |
| 8 | 40,493,357 | FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness - An Evaluation of Regulatory and Health Technology Assessment Decision Making. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40493357 | PubMed |
| 9 | 35,625,223 | New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35625223 | PubMed |
| 10 | 22,242,561 | Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. | Br J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22242561 | PubMed |
| 11 | 40,578,553 | Real-world analysis of ceftolozane/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infections. | J Glob Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40578553 | PubMed |
| 12 | 38,354,125 | Impact of obesity on intensive care unit outcomes in older patients with critical illness: A cohort study. | PLoS One | 2024 | https://conductscience.org/library/papers/38354125 | PubMed |
| 13 | 26,530,985 | A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. | Trials | 2015 | https://conductscience.org/library/papers/26530985 | PubMed |
| 14 | 34,234,480 | Relationship Between Multidrug-Resistant Enterobacterales and Obesity in Older Adults. | Infect Drug Resist | 2021 | https://conductscience.org/library/papers/34234480 | PubMed |
| 15 | 39,864,656 | Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA). | J Glob Antimicrob Resist | 2025 | https://conductscience.org/library/papers/39864656 | PubMed |
| 16 | 39,864,430 | A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. | Cardiorenal Med | 2025 | https://conductscience.org/library/papers/39864430 | PubMed |
| 17 | 31,086,308 | Antimicrobial resistance in nephrology. | Nat Rev Nephrol | 2019 | https://conductscience.org/library/papers/31086308 | PubMed |
| 18 | 35,058,571 | Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. | Int J Obes (Lond) | 2022 | https://conductscience.org/library/papers/35058571 | PubMed |
| 19 | 40,348,149 | Beyond the binary: integrating "real-world evidence" with randomized trials in contemporary health care. | J Clin Epidemiol | 2025 | https://conductscience.org/library/papers/40348149 | PubMed |
| 20 | 39,955,850 | A real-world investigation into prescribing patterns and effectiveness of ceftolozane/tazobactam among critically ill patients from SPECTRA. | Diagn Microbiol Infect Dis | 2025 | https://conductscience.org/library/papers/39955850 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SH2D1A | 4,068 | PubTator's text mining | https://conductscience.org/library/genes/4068 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41892463
GET https://conductscience.org/api/papers/v1/41892463/references?page=2